Muscat:Oman Investment Authority (OIA), in partnership with Saudi-based Oryx Isotopes Industry Company and in cooperation with the Ministry of Health and the Ministry of Finance, has announced the launch of the "Oman Nucleus" project. This initiative marks the beginning of the radiopharmaceutical industry in Oman with an investment of RO 6.5 million (USD 17 million).
According to Oman News Agency, the project is the first of its kind in Oman and aims to produce radiopharmaceuticals for diagnosis and treatment, operating within a public-private partnership model. This collaboration seeks to combine investment capabilities with industrial and technical expertise to develop a specialized medical sector.
The "Oman Nucleus" project is expected to provide hospitals and health centers in Oman with a local source of radiopharmaceuticals. It aims to expand nuclear medicine services, contributing to enhanced health security and the national economy, aligning with Oman Vision 2040 targets.
Sultan Salim Al Habsi, Minister of Finance, emphasized that this project embodies Oman's strategic direction towards strengthening public-private partnerships. These partnerships are seen as vital for enhancing public spending efficiency, stimulating investment, and developing public services by leveraging private sector capabilities.
Abdulsalam Mohammed Al Murshidi, President of Oman Investment Authority, highlighted the establishment of the joint company with Oryx Isotopes Industry Company, stating that it lays a foundation for a specialized industry crucial to the health sector. The "Oman Nucleus" project aims to build national capabilities for producing necessary radiopharmaceuticals, ensuring local sustainability of supplies.
Dr. Hilal Ali Al Sabti, Minister of Health, noted the project's importance in developing nuclear medicine services in Oman. The availability of radiopharmaceuticals will support the expansion of diagnostic examinations, enhance early disease detection, and provide targeted treatment options, improving healthcare outcomes for patients.
The project is managed by a joint entity of Oman Investment Authority and Oryx Isotopes Industry Company under a long-term agreement with the Ministry of Health. It seeks to establish an integrated facility for producing radiopharmaceuticals used in nuclear medicine imaging and targeted radiation therapy.
Local production aims to enhance the sustainability of radiopharmaceutical supplies, reduce import reliance, and strengthen the national health system's resilience. The project is poised to expand health services and potentially develop a regional hub for radiopharmaceuticals, leveraging Oman's logistical infrastructure and air connectivity.
Source Oman News Agency